Title : GIST treatment options after tyrosine kinase inhibitors.

Pub. Date : 2014 Sep

PMID : 24952730






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 IGF1R inhibitors as a class are not being developed because of the lack of significant efficacy in many clinical trials and the efficacy in WT GIST has been limited; to date drugs targeting VEGFR, such as sunitinib and regorafenib, appear to be the best agents available for this group of patients. regorafenib insulin like growth factor 1 receptor Homo sapiens